- Home
- NMCO vs PLRX Comparison
NMCO vs PLRX Comparison
Compare NMCO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | PLRX |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.6M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMCO | PLRX |
|---|---|---|
| Price | $10.22 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 207.6K | ★ 1.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $1.10 |
| 52 Week High | $11.64 | $14.26 |
Technical Indicators
Market Signals| Indicator | NMCO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 26.41 | 38.77 |
| Support Level | $10.16 | $1.20 |
| Resistance Level | $10.78 | $1.27 |
| Average True Range (ATR) | 0.12 | 0.08 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 9.68 | 29.17 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.